These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17548247)

  • 1. No association exists between E-cadherin gene polymorphism and tumor recurrence in patients with hepatocellular carcinoma after transplantation.
    Li XD; Wu LM; Xie HY; Xu X; Zhou L; Liang TB; Wang WL; Shen Y; Zhang M; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):254-8. PubMed ID: 17548247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of E-cadherin expression and recurrence of hepatocellular carcinoma.
    Huang GT; Lee HS; Chen CH; Sheu JC; Chiou LL; Chen DS
    Hepatogastroenterology; 1999; 46(27):1923-7. PubMed ID: 10430370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma].
    Chen XJ; Wu LM; Xu XB; Feng XW; Xie HY; Zhang M; Shen Y; Wang WL; Liang TB; Zheng SS
    Zhonghua Wai Ke Za Zhi; 2007 Oct; 45(19):1354-8. PubMed ID: 18241575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neural cadherin overexpression is a predictive marker for early postoperative recurrence in hepatocellular carcinoma patients.
    Seo DD; Lee HC; Kim HJ; Min HJ; Kim KM; Lim YS; Chung YH; Lee YS; Suh DJ; Yu E; Chun SY
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1112-8. PubMed ID: 17944884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma.
    Chien MH; Yeh KT; Li YC; Hsieh YH; Lin CH; Weng MS; Kuo WH; Yang SF
    J Surg Oncol; 2011 Sep; 104(3):299-304. PubMed ID: 21462191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation.
    Wu L; Xu X; Shen J; Xie H; Yu S; Liang T; Wang W; Shen Y; Zhang M; Zheng S
    J Surg Oncol; 2007 Jul; 96(1):62-8. PubMed ID: 17443726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma.
    Wang XQ; Luk JM; Leung PP; Wong BW; Stanbridge EJ; Fan ST
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):483-9. PubMed ID: 15701831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation among p130Cas, E-cadherin and beta-catenin expression, clinicopathologic significance and prognosis in human hepatocellular carcinoma.
    Guo C; Liu QG; Yang W; Zhang ZL; Yao YM
    Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):490-6. PubMed ID: 18842495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer.
    Lin J; Dinney CP; Grossman HB; Jhamb M; Zhu Y; Spitz MR; Wu X
    Clin Genet; 2006 Sep; 70(3):240-5. PubMed ID: 16922727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of E- and N-cadherin and clinicopathology in hepatocellular carcinoma.
    Cho SB; Lee KH; Lee JH; Park SY; Lee WS; Park CH; Kim HS; Choi SK; Rew JS
    Pathol Int; 2008 Oct; 58(10):635-42. PubMed ID: 18801083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter.
    Lim SO; Gu JM; Kim MS; Kim HS; Park YN; Park CK; Cho JW; Park YM; Jung G
    Gastroenterology; 2008 Dec; 135(6):2128-40, 2140.e1-8. PubMed ID: 18801366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation.
    Zou WL; Zang YJ; Chen XG; Shen ZY
    Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):145-51. PubMed ID: 18397848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinoma.
    Wang XQ; Luk JM; Garcia-Barcelo M; Miao X; Leung PP; Ho DW; Cheung ST; Lam BY; Cheung CK; Wong AS; Lau SS; So MT; Yu WC; Cai Q; Liu KS; Hui CK; Lau GK; Poon RT; Wong J; Fan ST
    Clin Cancer Res; 2006 Sep; 12(17):5248-52. PubMed ID: 16951245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E-cadherin gene polymorphisms and haplotype associated with the occurrence of epithelial ovarian cancer in Chinese.
    Li Y; Liang J; Kang S; Dong Z; Wang N; Xing H; Zhou R; Li X; Zhao X
    Gynecol Oncol; 2008 Feb; 108(2):409-14. PubMed ID: 18035404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MMP2 promoter polymorphism (C-1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation.
    Wu LM; Zhang F; Xie HY; Xu X; Chen QX; Yin SY; Liu XC; Zhou L; Xu XB; Sun YL; Zheng SS
    Clin Genet; 2008 Mar; 73(3):273-8. PubMed ID: 18177474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic value of E-cadherin, CD34 in the patients with hepatocellular carcinoma].
    Wu LQ; Lu Y; Lu HJ; Zhang B; Yang JY; Ma X
    Zhonghua Wai Ke Za Zhi; 2006 Jun; 44(11):774-7. PubMed ID: 16836930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of evidence for the association of E-cadherin gene polymorphism with increased risk or progression of prostate cancer.
    Tsukino H; Kuroda Y; Imai H; Nakao H; Qiu D; Komiya Y; Inatomi H; Hamasaki T; Kohshi K; Osada Y; Katoh T
    Urol Int; 2004; 72(3):203-7. PubMed ID: 15084762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of the serum level of soluble E-cadherin in patients with HCC.
    Soyama A; Eguchi S; Takatsuki M; Kawashita Y; Hidaka M; Tokai H; Nagayoshi S; Mochizuki S; Matsumoto S; Hamasaki K; Tajima Y; Kanematsu T
    Hepatogastroenterology; 2008; 55(85):1390-3. PubMed ID: 18795696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt-1 protein as a prognostic biomarker for hepatitis B-related and hepatitis C-related hepatocellular carcinoma after surgery.
    Lee HH; Uen YH; Tian YF; Sun CS; Sheu MJ; Kuo HT; Koay LB; Lin CY; Tzeng CC; Cheng CJ; Tang LY; Tsai SL; Wang AH
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1562-9. PubMed ID: 19423534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single nucleotide polymorphism in the promoter region of human alpha-fetoprotein (AFP) gene and its significance in hepatocellular carcinoma (HCC).
    Chen GG; Ho RL; Wong J; Lee KF; Lai PB
    Eur J Surg Oncol; 2007 Sep; 33(7):882-6. PubMed ID: 17433605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.